MedTrace Logo

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT02815007 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-06-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Chidamide with EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Conditions

  • Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Interventions

DRUG

Chidamide with EGFR-TKI

Chidamide and EGFR-TKI, dosage described in arm description.

Sponsors & Collaborators

  • Yuankai Shi

    lead OTHER

Principal Investigators

  • Yuankai Shi, Doctor · Cancer institute and hospital, Chinese academy of medical sciencees

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-03-31
Completion
2018-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02815007 on ClinicalTrials.gov